Seattle Genetics/Genmab's tisotumab’s cervical cancer efficacy falls off

It was always going to be tough for Genmab/Seattle Genetics’ tisotumab vedotin to come close to the 36-46% remission rate seen in a late-line cervical cancer cohort of an earlier trial. So it proved yesterday, with topline data from the Innova-204 study, run specifically in this cancer, showing a more modest response rate of 24%.